Most of us have had the experience: you walk into a room and cannot remember why, or spend five minutes searching for glasses that are on your head. These moments of forgetfulness can be alarming, especially when you have watched a parent or grandparent decline from Alzheimer’s disease.

The anxiety is understandable. But it often leads people to one of two mistakes: dismissing genuinely concerning symptoms as “just getting older,” or catastrophizing normal lapses into something they are not.

As a preventive neurologist, I spend a meaningful part of each consultation helping patients distinguish between these two things. The distinction matters, not only for peace of mind, but because it changes what we do next.

How Does Memory Loss in Alzheimer’s Differ From Normal Aging?

The short answer: normal aging makes memory slower, while early Alzheimer’s disease makes it leaky. With age, it takes longer to pull up a name or a detail, but the information is still stored, and it usually comes back later or with a hint. Some of this slowing begins as early as our 20s and 30s.1 In early Alzheimer’s, the brain has trouble storing new information in the first place. A reminder helps much less,2 and recent conversations, appointments and events are lost rather than delayed.

The second difference is what the memory change does to everyday life. Forgetting is normal at any age. Memory problems that make it hard to manage everyday tasks, such as driving, using the phone or finding your way home, are not.3

Key Point

In normal aging, the information is still in there; the filing system is slower, not corrupted. In early Alzheimer’s, new memories are not stored well, so cues and time do not bring them back, and the change starts to affect daily life.

Normal Aging vs. Early Alzheimer’s: A Side-by-Side Comparison

No single item below makes a diagnosis. What matters is the pattern, how often it happens, and whether it is a change from the person’s own baseline.

Typical age-related changes compared with patterns that warrant an evaluation for early Alzheimer’s disease
Area Normal aging Possible early Alzheimer’s
Recent memory Details of a conversation fade, but the gist stays. You may retell a story days later to someone who already heard it. Recent conversations and events are lost entirely. The same question or story comes up again and again, sometimes within one conversation.3
Recall with a cue A hint, a list or retracing your steps usually brings the memory back. Hints help much less, because the information was never stored well.2
Word-finding Sometimes forgetting which word to use; it usually arrives a few minutes later. Trouble having or following a conversation.3
Getting around A wrong turn in an unfamiliar place. Getting lost in places you used to know well.3
Judgment and finances A bad decision once in a while, or an occasional missed payment. Poor judgments and decisions much of the time, or trouble managing monthly bills.3
Time and dates Forgetting what day it is and working it out later. Losing track of the date or the time of year.3
Daily function Fully independent. You may lean more on lists and calendars. Complex tasks such as bills or medications take more effort. When someone else has to take them over, the threshold for dementia has been crossed.45
Awareness You notice your own lapses, often more than anyone else does. Family may notice more than the person does. Reduced awareness of memory problems in mild cognitive impairment predicts later progression to Alzheimer’s.6
Change over time Mild changes that build slowly over decades.1 A noticeable decline from your own baseline over months to a few years, which keeps progressing.7

What Does Normal Brain Aging Actually Look Like?

The brain changes with age. This is not pathology; it is biology. Some abilities, processing speed in particular, begin to shift in early adulthood, and the changes become easier to notice through our 60s and 70s.1 It takes longer to retrieve information or switch between tasks. Holding several things in mind at once, the mental whiteboard, gets harder. Tip-of-the-tongue moments become more frequent, but the word usually arrives a few minutes later, often unprompted.

What remains largely intact in healthy aging: long-term memory for meaningful events, general knowledge, language comprehension, and the ability to carry out familiar tasks without losing your way through them.

What Are the Early Warning Signs of Alzheimer’s Disease?

The following are not normal aging. None of them alone is diagnostic of Alzheimer’s disease. Many have other explanations, including sleep deprivation, thyroid problems, low vitamin B12, depression, or medication side effects.3 But they are clinical signals that call for evaluation rather than reassurance.

  1. Forgetting recent information and not recovering it. The conversation you had an hour ago or the appointment you made yesterday does not come back, even after retracing your steps. This reflects early involvement of the hippocampus, which forms new memories.
  2. Repeating the same question or story in one conversation. This is one of the signs family members notice first. The earlier exchange was never stored.
  3. Getting lost in familiar places, such as taking a wrong turn on a route driven hundreds of times.
  4. New trouble with money and paperwork: following a bill, balancing accounts or tracking a budget.
  5. Losing track of the month, the season or how long ago an important event happened.
  6. Difficulty following conversations, plots or multi-step instructions such as recipes and directions.
  7. Misplacing things in odd places, like the remote in the refrigerator, rather than on the usual counter.
  8. Declining judgment, such as falling for a scam that would once have been obvious.
  9. Withdrawal from work, hobbies or social life. Depression is always worth ruling out, but people with early cognitive decline sometimes step back from situations that expose their difficulties.
  10. Out-of-character mood or personality changes, such as new anxiety, irritability, suspiciousness or apathy. Mood changes are common early symptoms of Alzheimer’s and related diseases.5

Subjective Cognitive Decline, MCI or Dementia: Where Is the Line?

Cognitive symptoms sit on a spectrum. The dividing line that matters most is daily function.

Subjective cognitive decline is a change in memory or thinking that you notice but that standard tests do not detect.8 It is common and often benign. On average, though, it roughly doubles the risk of later dementia: in a meta-analysis of 28 studies, about 2.3 percent of older adults with memory complaints progressed to dementia each year (Mitchell, Acta Psychiatr Scand 2014).9 It warrants monitoring, not dismissal.

Mild cognitive impairment (MCI) means a decline that shows up on objective testing, while the person stays independent in daily life.4 Tasks such as paying bills or managing medications may take more effort but are still done without help.5 In specialist memory clinics, about 10 percent of people with MCI progress to dementia each year; in community studies, about 5 percent (Mitchell and Shiri-Feshki, Acta Psychiatr Scand 2009). Most people with MCI had not developed dementia even after 10 years of follow-up.10

Dementia is diagnosed when cognitive decline interferes with independence in everyday activities.5

What Do Clinicians Check to Tell Early Alzheimer’s From Normal Aging?

The Alzheimer’s Association clinical practice guideline published in late 2024 for evaluating cognitive symptoms in primary and specialty care makes one point especially clear: a clinician should not assume memory or behavior changes are “normal aging” without an appropriate evaluation.5 When the patient, a family member or a clinician reports a change, the guideline recommends a structured evaluation. These are its main parts.

A change from the person’s own baseline, confirmed by someone who knows them

The history should come from the patient and from an informant, usually a spouse, adult child or close friend. It covers changes in memory and thinking, daily activities, mood and behavior, and movement and senses.5 Informant questionnaires add a lot. The AD8, an eight-question informant interview, separated very mild dementia from normal aging with 74 percent sensitivity and 86 percent specificity in its validation study (Galvin, Neurology 2005).11

Daily function

Clinicians ask about finances, medications, driving, cooking and appointments. Independence in these tasks separates MCI from dementia.4

A brief, validated cognitive test

Brief screening tests differ in sensitivity. In its original validation study, the Montreal Cognitive Assessment (MoCA) detected 90 percent of people with MCI, while the Mini-Mental State Examination detected 18 percent (Nasreddine, J Am Geriatr Soc 2005).12 The guideline stresses that a test score should never be read in isolation. When a brief test is normal but concern remains, for example in people with very high education, referral for neuropsychological testing is the next step.5

Reversible and contributing causes

Memory problems can come from conditions other than Alzheimer’s, and these often improve with treatment.3 The guideline’s first-line workup includes blood tests such as a complete blood count, metabolic panel, thyroid-stimulating hormone (TSH) and vitamin B12, along with structural brain imaging, preferably MRI. It also calls for a review of contributors such as medications that impair cognition, obstructive sleep apnea, depression and other mood disorders, and heavy alcohol use.5

Biomarkers and the 2024 revised criteria

In 2024, an Alzheimer’s Association workgroup revised the criteria for diagnosing Alzheimer’s disease. The revision defines Alzheimer’s biologically, by the presence of its brain changes, rather than by symptoms alone. Under it, one abnormal “Core 1” biomarker is enough to establish the diagnosis: amyloid PET, an approved spinal fluid test, or an accurate blood test, especially p-tau217. The authors also state that clinical use of these biomarkers is, for now, intended for people with symptoms, not for people who are cognitively unimpaired.7

Blood tests are now part of this workup. A 2025 Alzheimer’s Association guideline says blood tests with at least 90 percent sensitivity and 75 percent specificity can be used for triage, and tests with at least 90 percent sensitivity and specificity can substitute for amyloid PET or spinal fluid testing. That guidance applies to patients with cognitive impairment seen in specialized memory care. The panel warned that many commercial tests do not meet these thresholds.13 In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s, for adults 55 and older seen in specialized care with signs and symptoms of cognitive decline. It is not a screening or stand-alone test.14

Key Point for Clinicians

Mild symptoms deserve a structured evaluation, not reassurance: a history that includes an informant, a check of daily function, a validated cognitive test, labs including TSH and B12, a medication and sleep review, and imaging. Biomarkers belong inside that evaluation, not in place of it.

What Happens in the Brain Before Symptoms Appear?

This is perhaps the most important and least widely understood part of Alzheimer’s disease. In families with an inherited form of the disease, amyloid changes in spinal fluid appeared about 25 years before expected symptom onset, and amyloid was visible on PET scans about 15 years before (Bateman, NEJM 2012).15 In people with normal thinking, the share with amyloid buildup rose from about 10 percent at age 50 to 44 percent at age 90 (Jansen, JAMA 2015).16

Many of those people will never develop dementia, so an abnormal biomarker without symptoms is a risk finding, not a diagnosis. But the timeline shows why the more useful question is often: what is my underlying risk, and what can I do about it now?

Common Questions

Is it normal to forget words as you get older?

Yes. Occasional tip-of-the-tongue moments are a normal part of aging, and the word usually comes back later. It is more concerning when word problems make it hard to follow or take part in conversations, or when they become frequent and keep worsening.

Can stress, poor sleep or depression cause memory problems that look like Alzheimer’s?

Yes. Depression, anxiety, sleep problems, thyroid disease, low vitamin B12, alcohol and some medications can all affect memory, and these problems often improve with treatment. That is why an evaluation looks for them first. Mood changes can also be an early sign of a neurodegenerative disease, so they are worth discussing either way.

Does mild cognitive impairment always turn into Alzheimer’s?

No. MCI has many possible causes, and many people with MCI stay stable for years. Its course depends on the cause, which is why identifying the cause after an MCI diagnosis matters.

Should I get an Alzheimer’s blood test if I have no symptoms?

Current guidelines are written for people who already have symptoms, and every FDA-cleared Alzheimer’s blood test is cleared only for them. In someone without symptoms, a positive result indicates higher risk, not a diagnosis. If you are considering testing, do it with a clinician who can explain what the result will and will not tell you, and what you would do differently.

When Should You Get Evaluated?

Consider a formal evaluation if any of these apply:

This is not cause for alarm; it is cause for information. A comprehensive brain health assessment brings together history, cognitive testing, labs and imaging to separate normal aging from a pattern that needs a diagnosis.

Equally, if you have a family history of Alzheimer’s disease, carry an APOE4 allele, or simply want to understand your baseline while your brain is healthy, a preventive evaluation makes sense regardless of symptoms. A baseline measured in midlife gives you something to compare against later. It is also the time to act on modifiable risk: the 2024 Lancet Commission estimated that addressing 14 modifiable risk factors could in theory prevent or delay about 45 percent of dementia cases worldwide.17 If you are weighing biomarker testing, read what Alzheimer’s blood tests can and cannot tell you first. For ongoing care with longer visits and follow-up over time, see concierge preventive neurology.

The patients I worry least about are the ones who come in early. The ones I worry about are the ones who waited until there was something obvious to bring them in.


Dr. Nadir Bilici, MD, DipIBLM, is a neurologist and lifestyle medicine physician specializing in preventive neurology, Alzheimer’s prevention, and cognitive risk assessment. He sees patients by telehealth in the states where he is licensed, with in-person appointments available on a select basis.

References

  1. Salthouse TA. When does age-related cognitive decline begin? Neurobiol Aging. 2009;30(4):507-514. doi:10.1016/j.neurobiolaging.2008.09.023
  2. Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69(19):1859-1867. doi:10.1212/01.wnl.0000279336.36610.f7
  3. National Institute on Aging. Memory problems, forgetfulness, and aging. Content reviewed November 22, 2023. nia.nih.gov
  4. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008
  5. Atri A, Dickerson BC, Clevenger C, et al. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care. Alzheimers Dement. 2025;21(6):e14333. doi:10.1002/alz.14333
  6. Gerretsen P, Chung JK, Shah P, et al. Anosognosia is an independent predictor of conversion from mild cognitive impairment to Alzheimer's disease and is associated with reduced brain metabolism. J Clin Psychiatry. 2017;78(9):e1187-e1196. doi:10.4088/JCP.16m11367
  7. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143-5169. doi:10.1002/alz.13859
  8. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001
  9. Mitchell AJ, Beaumont H, Ferguson D, et al. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439-451. doi:10.1111/acps.12336
  10. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252-265. doi:10.1111/j.1600-0447.2008.01326.x
  11. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559-564. doi:10.1212/01.wnl.0000172958.95282.2a
  12. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x
  13. Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. doi:10.1002/alz.70535
  14. U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer's disease. May 16, 2025. fda.gov
  15. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. doi:10.1056/NEJMoa1202753
  16. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668
  17. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0

Written and medically reviewed by Nadir Bilici, MD, DipIBLM. Published March 2026 · Medically reviewed on . What changed: Rewritten with a side-by-side comparison table and updated to current 2024 criteria and blood-biomarker evidence. See our editorial policy.